Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Surgery
Published in: Journal of Gastrointestinal Surgery 6/2015

01-06-2015 | Original Article

Predictors of Long-Term Diabetes Remission After Metabolic Surgery

Authors: Ming Hsien Lee, Wei-Jei Lee, Keong Chong, Jung-Chien Chen, Kong-Han Ser, Yi-Chih Lee, Shu-Chun Chen

Published in: Journal of Gastrointestinal Surgery | Issue 6/2015

Login to get access

Abstract

Background Data

Bariatric/metabolic surgery has been proposed for the treatment of inadequately controlled type 2 diabetes mellitus (T2DM) in obese patients. However, prediction on successful long-term remission of T2DM after metabolic surgery has not been clearly studied. Our objectives were to evaluate rates of long-term remission of T2DM after metabolic surgery and determine the independent predictors of remission.

Methods

Outcomes of 157 patients who underwent metabolic surgery between 2006 and 2009 and who had complete 5-year follow-up data were assessed. Prolonged complete remission was defined as glycated hemoglobin (HbA1c) less than 6 % without diabetes medication up to 5 years. Predictors of prolonged remission studies included patient characteristics such as glucose level, HbA1c, body weight, waist circumference, blood pressure, total cholesterol, LDL, triglyceride, uric acid, AST, alanine transaminase (ALT), albumin, insulin, C-peptide, iron, calcium, complete blood cell count, the ABCD score (a multidimensional grading system composed of age, body mass index (BMI), C-peptide levels, and duration of T2DM), and postoperative weight loss.

Results

At 5 years after surgery, the weight loss was 27.1 % and the mean BMI decreased from 39.8 to 28.8 kg/m2. The mean HbA1c decreased from 8.3 to 6.0 %. A significant number of patients had improvement in their glycemic control, including 97 (71.3 %) patients who had complete remission (HbA1c < 6.0 %), 27 (19.9 %) partial remission (HbA1c < 6.5 %), and 12 (8.8 %) improved condition (HbA1c < 7 %). In univariate analysis, patients with prolonged T2DM remission after surgery were younger and heavier; had a wider waist, higher C-peptide, shorter duration of T2DM, higher liver enzyme, higher insulin resistance, higher C-peptide level, and higher white blood cell count; were taking smaller insulin dosage; had higher ABCD score; and had greater weight loss than those without remission. Multivariate logistical regression analyses showed that the ABCD score and weight loss were the only predictors of remission after metabolic surgery.

Conclusions

Metabolic surgery is a treatment option for patients with obesity and T2DM. Baseline ABCD score and weight loss have a major influence on outcome.
Literature
1.
Zimmer P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. JAMA 2013; 414:782–787.
2.
Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31–40.CrossRefPubMed
3.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358:2545–2559.CrossRef
4.
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–958.CrossRefPubMed
5.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.CrossRefPubMedCentralPubMed
6.
Hiroki Yokoyam, Okudaira M, Otani T, et al. High incidence of diabetic nephropath in early-onset Japanese NIDDM patients. Diabetes Care 1998;7:1080–1085CrossRef
7.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–1737.CrossRefPubMed
8.
Sjostrom L, Narbro K, Sjostrom D, et al. Effect of bariatric surgery on mortality in Swedish obese subjects. NEJM 2007;357:741–752.CrossRefPubMed
9.
Lee WJ, Huang MT, Wang W, et al. Bariatric surgery: Asia-Pacific perspective. Obes Surg 2005;15:751–757.CrossRefPubMed
10.
11.
Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316–323PubMed
12.
Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146:143–148.CrossRefPubMed
13.
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567–1576.CrossRefPubMedCentralPubMed
14.
Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The diabetes surgery study randomized clinical trial. JAMA 2013;309(21):2240–2249.CrossRefPubMedCentralPubMed
15.
Liang Z, Wu Q, Chen B, Yu P, Zhao H, Quyang X. Effect of laparoscopic Roux-en-Y gastric bypass for type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Prac 2013;101(1):50–56.CrossRef
16.
Wentworth J, Playfair J, Lavrie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomized controlled trial. Lancet Diabetes Endocrinol 2014;2(7):545–52.
17.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes. N Engl J Med. 2014;370(21):2002–2013CrossRefPubMed
18.
Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. The New England Journal of Medicine. 2004;351(26):2683–2693.CrossRefPubMed
19.
DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 2010;6:249–253.CrossRefPubMed
20.
Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010;6:254–259.CrossRefPubMed
21.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:S5–S20.
22.
23.
Matthews DR, Hosker JP, Rudensky AS, et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412–419.CrossRefPubMed
24.
Lee WJ, Yu PJ, Wang W, et al. Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial. Ann Surg 2005;242:20–28CrossRefPubMedCentralPubMed
25.
Ser KH, Lee WJ, Lee YC, Chen JC, Su YH, Chen SC. Experience in laparoscopic sleeve gastrectomy for morbidly obese Taiwanese: staple-line reinforcement is important for preventing leakage. Surg Endosc 2010;24(9):2253–2259.CrossRefPubMed
26.
Lee WJ, Hur K, Lakadawala M, Kasama K, et al. Predicting the Success of Metabolic Surgery: Age, Body Mass Index, C-peptide, and Duration Score. Surg Obes Relat Dis 2013; 9: 379–384.CrossRefPubMed
27.
Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes care. 2013;36(1):20–26.CrossRefPubMedCentralPubMed
28.
Dixon J, Hur KY, Lee WJ, et al. Gastric bypass in type 2 diabetes with BMI < 30: weight and weight loss have a major influence on outcomes. Diabet. Med. 2013; 30: e127–e134.CrossRefPubMed
29.
Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: A systematic review. JAMA 2013;309:2250–2261.CrossRefPubMed
30.
Lebovitz HE. Metabolic surgery for type 2 diabetes with BMI < 35 Kg/m2: An endocrinologist’s perspective. Obesity Surg 2013;23:800–808.CrossRef
31.
Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diab Care 2012;35:1420–1426.CrossRef
32.
Lakadawala M, Shaikh S, Bandukwala S, et al. Roux-en-Y gastric bypass stands the test of time: 5-year results in low body mass index (30–35) Indian patients with type 2 diabetes mellitus. Surg Obes Relat Dis 2013;9:370–378.CrossRef
33.
Brethauer SA, Amino A, Ramero-Talamas H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013;258:628–637.PubMedCentralPubMed
34.
Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102.CrossRefPubMed
35.
Sultan S, Gupta D, Parikh M, et al. Five-year outcomes of patients with type 2 diabetes who underwent laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2010;6:373–376.CrossRefPubMed
36.
Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 2013;216:545–545.CrossRefPubMed
37.
Heneghan HM, Cetin D, Navaneethan SD, et al. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis 2013;9:7–14.CrossRefPubMed
38.
Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 202;308:1122–1131.
39.
Dixon JB, O’Brien PE. Selecting the optimal patient for LAP-BAND placement. Am J Surg 2002;184:17–20.CrossRef
40.
Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237:751–758.PubMedCentralPubMed
41.
Hamza N, Abbas MH, Darwish A, Shafeek Z, New J, Ammori BJ. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis 2011;7:691–696.CrossRefPubMed
42.
Blackstone R, Bunt JC, Cortes MC, Sugerman HJ. Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis 2012;8:548–555.CrossRefPubMed
43.
Still CD, Wood GC, Benotti P, et al. A probability score for preoperative prediction of type 2 diabetes remission following RYGB surgery. Lancet Diabetes Endocrinol 2014;2:38–45.CrossRefPubMedCentralPubMed
44.
Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340–1348.CrossRefPubMed
45.
Lee WJ, Wang W, Lee YC, et al. Effects of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI > 35 and < 35 Kg/m2. J Gastrointest Surg 2008;12:945–952.CrossRefPubMed
46.
Kim JW, Cheong JH, Hyung WJ, Choi SH, Noh SH. Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol. 2012;18:49–54.CrossRefPubMedCentralPubMed
47.
Lee WJ, Chong K, Ser KH, et al. C-peptide Predicts the Remission of Type 2 Diabetes after Bariatric Surgery. Obesity Surgery 2012; 22:293–298.CrossRefPubMed
48.
Aarts EO, Janssen J, Janssen IM, Berends FJ, Telting D, de Boer H. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obes Surg 2013;23:867–873.CrossRefPubMed
49.
Sjostrom L. Review of the key results from the Swedish obese subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Int Med 2013;273:219–234.CrossRef
50.
Carrison LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Sweden obese subjects. NEJM 2012;367:2683–2693.
51.
Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009;150:2518–25.CrossRefPubMed
52.
DePaula AL, Macedo AL, Rassi N, et al. Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc 2008; 22(12):2670–8.CrossRefPubMed
53.
Ramos AC, Galvao N, de Souza YM, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 Kg/m2 (LBMI). Obes Surg 2009;19:307–311.CrossRefPubMed
Metadata
Title
Predictors of Long-Term Diabetes Remission After Metabolic Surgery
Authors
Ming Hsien Lee
Wei-Jei Lee
Keong Chong
Jung-Chien Chen
Kong-Han Ser
Yi-Chih Lee
Shu-Chun Chen
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 6/2015
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-2808-1

Other articles of this Issue 6/2015

Journal of Gastrointestinal Surgery 6/2015 Go to the issue

How I do it

Single-Incision Laparoscopic Biliary Bypass for Malignant Obstructive Jaundice

Original Article

Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis

Original Article

Impact of Anatomic Location on Locally Recurrent Rectal Cancer: Superior Outcome for Intraluminal Tumour Recurrence

2014 SSAT Plenary Presentation

Do Adverse Childhood Experiences Affect Surgical Weight Loss Outcomes?

Letter to the Editor

Perioperative blood transfusion as a poor prognostic factor after aggressive surgical resection for hilar cholangiocarcinoma

Review Article

Benign Solid Tumors of the Liver: Management in the Modern Era